Secondary Objective Clause Samples
The Secondary Objective clause defines additional goals or outcomes that a party aims to achieve beyond the primary purpose of the agreement. Typically, this clause outlines supplementary targets, such as improving efficiency, fostering collaboration, or achieving certain milestones that support the main objective. By clearly stating these secondary aims, the clause helps ensure that both parties are aligned on broader expectations and can measure success beyond the primary deliverables, thereby promoting transparency and mutual understanding.
Secondary Objective. Not applicable.
Secondary Objective. The secondary objective of this study are to assess the efficacy of ricolinostat for non-pain diabetic peripheral neuropathic signs and to further assess efficacy in painful DPN.
Secondary Objective. The secondary objective of this study is to assess the safety and tolerability of aramchol administered orally in subjects with hepatic impairment.
Secondary Objective. The secondary objective is: To determine the effect of QD TVB-2640 for 12 weeks versus placebo in subjects with ▇▇▇▇ on: – Lipid and lipoprotein parameters, including low-density lipoprotein cholesterol (LDL-C), non-LDL-C, high-density lipoprotein cholesterol (HDL-C), non-HDL- C, total cholesterol, TG, apolipoprotein B (ApoB), and lipoprotein(a) (Lp[a]) particles. – ▇▇▇▇ and fibrosis biomarkers including cytokeratin-18 (CK-18), fibrosis-4 (FIB- 4), and enhanced liver function (ELF) or FIBROSpect 2 or ProC3 test. – Eicosanoid panel.
Secondary Objective. The secondary objective of this study is to evaluate the safety and tolerability of 600 mg oral TPOXX administered BID for 7 days in adult subjects weighing more than 120 kg.
Secondary Objective. To evaluate the safety and tolerability of TNX-601 ER (tianeptine hemioxalate extended-release tablets) monotherapy in the treatment of MDD.
Secondary Objective. After achieving the primary objective, Steroids, Ltd. will demonstrate the new process works by producing 5 gms of final product meet the FDA purity requirements.
Secondary Objective. The secondary objective of the study is to evaluate safety and tolerability of LOXO-305 in subjects with impaired hepatic function and matched-control healthy subjects.
Secondary Objective. To assess the change from baseline in eGFR in bardoxolone methyl-treated patients at Week 100. • To assess the safety of bardoxolone methyl relative to placebo after 100 weeks of treatment. • To assess the change from baseline in eGFR in bardoxolone methyl-treated patients at Week 104 following a 4-week drug treatment withdrawal period.
Secondary Objective. The secondary objective of the study is to evaluate safety and tolerability of LOXO-305 in subjects with impaired renal function and matched-control healthy subjects.